The goal of this clinical trial is to compare the effectiveness of several treatment regimens for stage I triple negative breast cancer before surgery. The mai…

Triple-Negative Breast Cancer (TNBC)

~Estimated

~$10 – $6,250

University of Texas Southwestern Medical CenterNCT07786428

Phase 1

Phase 1/2 Trial of a Combination Immunotherapy Treatment for Solid Tumors Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy

The objective of this study is to evaluate the safety, feasibility, and preliminary antitumor activity of this multi-component immunotherapy strategy in patien…

Triple-Negative Breast Cancer (TNBC)

~Estimated

~$10 – $8,750

BreakBio CorpNCT07762703

Phase 1

A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Assess Safety, Tolerability, and Efficacy of EXS74539 as Monotherapy in Participants With Select Solid Tumors

The primary purpose of this study is to determine the safety, tolerability, and maximum tolerated dose (MTD) of EXS74539 (REC-4539) in participants with select…

Solid TumorSmall Cell Lung Cancer (SCLC)High Grade Neuroendocrine Cancer+9 more

~Estimated

~$10 – $8,750

Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.NCT07517198